Austral Capital Partners

Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus. The proprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis. Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537. Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio. Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile.

SCOPIX is the market leader in intelligent video analytics for retailers, CPG companies and manufactures. Our Real.Suite ™ family of cloud based solutions collects data and returns timely, actionable information via a web based portal to store personnel, regional managers and corporate executives to help them maximize the customer experience throughout the entire store. SCOPIX solutions are proven to enhance retail business operations, drive sales and maximize profits.

Junar powers the Data Economy by delivering the easiest-to-use, cloud-based Open Data platform. For innovative organizations, Junar is the fastest way to publish data. The Junar platform enables businesses, governments, and organizations to free their data to drive new opportunities, collaboration, and transparency. Some of the world's leading companies trust Junar with their most valuable assets: their data and the end users who are viewing and using it.

Nimbic is a provider of SaaS-based, cloud computing electronic design automation (EDA) solutions. Nimbic enables high-speed and high-capacity 3D electromagnetic signal integrity, power integrity and EMI analysis field solutions for the microelectronics industry. Nimbic's global customers include Texas Instruments, Renesas, Toshiba, Tabula and Panasonic. Nimbic's nCloud solution facilitates efficient and robust chip-package-system co-design while significantly reducing time-to-market and costs. Nimbic's accelerated technology delivers unprecedented capacity handling, significantly faster speed than current methodologies, and the ability to span the entire design cycle in 3D IC, package and system simulations, while maintaining uncompromising Maxwell accuracy.

Nimbic is a provider of SaaS-based, cloud computing electronic design automation (EDA) solutions. Nimbic enables high-speed and high-capacity 3D electromagnetic signal integrity, power integrity and EMI analysis field solutions for the microelectronics industry. Nimbic's global customers include Texas Instruments, Renesas, Toshiba, Tabula and Panasonic. Nimbic's nCloud solution facilitates efficient and robust chip-package-system co-design while significantly reducing time-to-market and costs. Nimbic's accelerated technology delivers unprecedented capacity handling, significantly faster speed than current methodologies, and the ability to span the entire design cycle in 3D IC, package and system simulations, while maintaining uncompromising Maxwell accuracy.

Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus. The proprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis. Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537. Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio. Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile.

Bio Architecture Lab is a pioneer in the application of synthetic biology and enzyme design to the development of biofuels and renewable chemicals from aquafarmed, native macroalgae (seaweed), which is a low cost, scalable, and sustainable biomass.

Atakama Labs is a developer, publisher and operator of social games, focused on meaningful games. They are making games that will make the world a better place, while entertaining and surprising their players. Their games tend to be free to play so that everyone can enjoy them. They develop primarily in Chile and publish their products across the globe, both directly and together with partners, depending on the platform and territory. Atakama is backed by Austral Capital and the COPEC-UC Fund, two venture capital funds.

Paperless is an electronic receipts and electronic document management company in Latin America, processing over two billion documents per year for global enterprise businesses.